35 terminated. 35 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 35 | Terminated 35 |
| Phase 1 | 3 | Terminated 3 |
| Phase 3 | 3 | Terminated 3 |
Follow Glomerulonephritis: new trials by email Literature Review of Glomerulonephritis trials Research Report on Glomerulonephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE) zetomipzomib, placebo - Lupus Nephritis | Phase 2 | Terminated | Kezar Life Sciences, Inc. | 84 | 2023-11-03 | 2025-12-05 |
| Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy Peginterferon Alfa-2A 180 MCG/ML Injectable Solution - Membranous Nephropathy | Phase 2 | Terminated | Centre Hospitalier Universitaire de Nice | 4 | 2023-09-14 | 2026-06-18 |
| Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy SHR-2010 Injection, Placebo - Primary IgA Nephropathy | Phase 2 | Terminated | Guangdong Hengrui Pharmaceutical Co., Ltd | 53 | 2023-06-04 | 2025-03-05 |
| KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen - Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III | Phase 1 / Phase 2 | Terminated | Kyverna Therapeutics | 6 | 2023-04-28 | 2026-08-31 |
| Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN) Daxdilimab, Placebo (Normal Saline) - Lupus Nephritis | Phase 2 | Terminated | Amgen | 19 | 2023-04-26 | 2025-03-24 |
| A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014) efgartigimod IV, placebo - Membranous Nephropathy | Phase 2 | Terminated | argenx | 8 | 2023-02-20 | 2024-11-22 |
| KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen - Lupus Nephritis, Lupus Nephritis - WHO Class III | Phase 1 / Phase 2 | Terminated | Kyverna Therapeutics | 2 | 2022-12-01 | 2026-08-31 |
| Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V Iptacopan (part 1), Iptacopan (part 2), Placebo + standard of care - Lupus Nephritis | Phase 2 | Terminated | Novartis Pharmaceuticals | 81 | 2022-08-10 | 2026-10-15 |
| Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) VB119 - Minimal Change Disease, Focal Segmental Glomerulosclerosis | Phase 2 | Terminated | Tenet Medicines | 1 | 2022-05-03 | 2024-04-22 |
| Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN) AT-1501 - IgA Nephropathy, IgAN | Phase 2 | Terminated | Eledon Pharmaceuticals | 24 | 2022-03-21 | 2024-03-26 |
| Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN) BCX9930 - Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy | Phase 2 | Terminated | BioCryst Pharmaceuticals | 2 | 2022-02-18 | 2024-05-02 |
| Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) ALXN2050, Placebo - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 100 | 2022-01-14 | 2025-10-15 |
| A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy Telitacicept 160mg, Telitacicept 240mg, Placebo - IgA Nephropathy | Phase 2 | Terminated | RemeGen Co., Ltd. | 15 | 2021-11-04 | 2023-12-06 |
| An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases GFB-887 - Kidney Diseases, Glomerulosclerosis | Phase 2 | Terminated | Goldfinch Bio, Inc. | 31 | 2021-07-27 | 2022-11-15 |
| Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy VB119 - Membranous Nephropathy | Phase 1 / Phase 2 | Terminated | Tenet Medicines | 6 | 2021-05-05 | 2026-02-12 |
| Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) Ravulizumab, Placebo, Background Therapy - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 123 | 2021-01-19 | 2026-01-22 |
| A Study of Guselkumab in Participants With Active Lupus Nephritis Guselkumab Dose 1, Placebo, Guselkumab Dose 2 - Lupus Nephritis | Phase 2 | Terminated | Janssen Research & Development, LLC | 33 | 2020-09-15 | 2025-03-30 |
| A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease GFB-887, Placebo - Kidney Diseases, Diabetic Nephropathies | Phase 2 | Terminated | Goldfinch Bio, Inc. | 96 | 2020-07-28 | 2022-11-15 |
| Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy AVB-S6-500 - IgA Nephropathy | Phase 2 | Terminated | Aravive, Inc. | 1 | 2019-11-27 | 2022-02-10 |
| Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy LNP023, Rituximab - Idiopathic Membranous Nephropathy | Phase 2 | Terminated | Novartis Pharmaceuticals | 37 | 2019-11-23 | 2024-10-09 |
Showing 20 of 35. Sign in to see all of them.
Lupus Nephritis (15) · Glomerulonephritis, IGA (11) · Proteinuria (7) · Glomerulonephritis, Membranous (6) · Glomerulosclerosis, Focal Segmental (5) · Kidney Diseases (5) · Lupus Erythematosus, Systemic (4) · Nephritis (4) · Autoimmune Diseases (2) · Glomerulonephritis, Membranoproliferative (2) · Nephrosis (2) · Nephrosis, Lipoid (2) · Urologic Diseases (2) · Acute Kidney Injury (1)
Female Urogenital Diseases (35) · Female Urogenital Diseases and Pregnancy Complications (35) · Male Urogenital Diseases (35) · Urogenital Diseases (35) · Urologic Diseases (33) · Nephritis (31) · Kidney Diseases (30) · Immune System Diseases (29) · Autoimmune Diseases (26) · Skin and Connective Tissue Diseases (16) · Connective Tissue Diseases (15) · Lupus Erythematosus, Systemic (11) · Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (7)
Mycophenolic Acid (4) · Adrenal Cortex Hormones (3) · BIIB023 (2) · Cyclophosphamide (2) · Rituximab (2) · TACI receptor-IgG Fc fragment fusion protein (2) · fludarabine (2) · CCX140-B (1) · Etanercept (1) · Infliximab (1) · Interferon-alpha (1) · KZR-616 (1) · PF-06730512 (1) · Plasma Exchange (1) · Plasmapheresis (1)
Alexion Pharmaceuticals, Inc. (3) · Amgen (2) · Biogen (2) · Goldfinch Bio, Inc. (2) · Kyverna Therapeutics (2) · Novartis Pharmaceuticals (2) · Tenet Medicines (2) · Alnylam Pharmaceuticals (1) · Aravive, Inc. (1) · Aurinia Pharmaceuticals Inc. (1) · BioCryst Pharmaceuticals (1) · Bristol-Myers Squibb (1) · Centre Hospitalier Universitaire de Nice (1) · EMD Serono (1) · EMD Serono Research & Development Institute, Inc. (1)
United States (25) · Spain (13) · United Kingdom (10) · Germany (9) · Argentina (8) · China (8) · France (8) · Italy (8) · Malaysia (8) · Taiwan (8) · Australia (7) · Mexico (7) · Philippines (7) · Poland (7) · Brazil (6)
Carla M Nester, MD, MSA, FASN (1) · David Wofsy, MD (1) · Falk Hiepe, MD (1) · Fernando C. Fervenza, M.D., Ph.D. (1) · Francoise Desir (1) · Hong Zhang, MD, PHD (1) · Josef S Smolen, MD (1)
PMID 37528520, PMID 38299639, PMID 21325353, PMID 22325903, PMID 34169203, PMID 36423588, PMID 38724717, PMID 39455063, PMID 39673415, PMID 39899371
2018 (3), 2019 (2), 2016 (1), 2017 (1), UL1RR024150 (1)